Latanoprost Stada

Latanoprost, the active ingredient in Latanoprost Stada, is a prostaglandin analog presented as eye drops for ocular use. It lowers intra‑ocular pressure and is indicated for primary open‑angle glaucoma and ocular hypertension in adult patients. GNH USA supplies Latanoprost Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Latanoprost Stada belongs to the prostaglandin analog class and is used to manage conditions that involve elevated intra‑ocular pressure. - Primary open‑angle glaucoma: reduces intra‑ocular pressure to slow disease progression. - Ocular hypertension: lowers eye pressure to prevent conversion to glaucoma. - Secondary open‑angle glaucoma: decreases pressure in eyes with secondary forms of the disease.

Latanoprost may cause ocular and systemic reactions.

Common Side Effects: - Eye redness: mild conjunctival hyperemia. - Eyelash growth: increased length and thickness. - Iris darkening: gradual increase in brown pigmentation. - Eye irritation: transient burning or stinging.

Serious or Rare Side Effects: - Uveitis: inflammation of the uveal tract. - Corneal edema: swelling of the cornea affecting vision. - Severe allergic reaction: swelling, itching, or rash requiring medical attention.

Before using Latanoprost Stada, consider the following precautions. - Monitor intra‑ocular pressure: ensure therapeutic response and adjust therapy if needed. - Avoid use in active ocular inflammation: may exacerbate conditions such as uveitis. - Caution in patients with a history of herpetic eye disease: risk of reactivation. - Assess contact lens wearers: discontinue lenses before and after instillation. - Store at ambient temperature: keep in original container, protect from moisture and light.

Latanoprost Stada can interact with other ocular or systemic agents.

Major Interactions (Avoid): - Concomitant use with other prostaglandin analog eye drops: may increase local side effects. - Use with ocular anti‑inflammatory steroids: can reduce prostaglandin efficacy.

Moderate Interactions (Monitor Closely):\n- Topical corticosteroids: may diminish pressure‑lowering effect. - Adrenergic agonist eye drops: potential additive ocular irritation. - Contact lens solutions: may cause transient discomfort or blurred vision.